Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for
Eteplirsen on Wednesday, July 24, 2013
CAMBRIDGE, MA -- (Marketwired) -- 07/23/13 -- Sarepta Therapeutics,
Inc. (NASDAQ: SRPT), a developer of innovative RNA-based
therapeutics, today announced it will hold a conference call at 8:00
a.m. EDT (5:00 a.m. PDT) on Wednesday, July 24, 2013, to provide a
regulatory update for eteplirsen, its lead product candidate for the
treatment of Duchenne muscular dystrophy (DMD).
The conference call may be accessed by dialing 800.446.2782 for
domestic callers and 847.413.3235 for international callers. The
passcode for the call is 35357086. Please specify to the operator
that you would like to join the "Sarepta Therapeutics Regulatory
Update Call." The conference call will be webcast live under the
events section of Sarepta's website at www.sarepta.com and will be
archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class
RNA-based therapeutics to improve and save the lives of people
affected by serious and life-threatening rare and infectious
diseases. The Company's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential
treatments for some of the world's most lethal infectious diseases.
Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.
For more information, please visit us at www.sarepta.com.
Sarepta Investor Contact:
Sarepta Media Contact:
Press spacebar to pause and continue. Press esc to stop.